

BIBLIOGRAFÍA

1. American Conference of Governmental Industrial Hygienists. 2003. TLVs, BEIs, threshold limits values for chemical substances and physical agents. Biological exposure indexes. Cincinnati: ACGIH.
2. Bar-Sela S, Levy M, Westin JB, Laster R, Richter ED. 1992. Medical findings in nickel-cadmium battery workers. *Isr J Med Sci.* 28(8-9):578-83.
3. Bar-Sela S, Reingold S, Richter ED. 2001. Amyotrophic lateral sclerosis in a battery-factory worker exposed to cadmium *Int J Occup Environ Health.* 7(2):109-12.
4. Boll MC, Alcaraz-Zubeldia M, Montes S, Murillo-Bonilla L, Rios C. 2003. Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients. *Neurochem Res.* 28(5):699-703.
5. Brooks BR. 1994. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. *J Neurol Sci.* 124:96-107.
6. Brooks BR. 1996. Natural history of ALS: symptoms, strength, pulmonary function, and disability. *Neurology.* (4 Suppl 2):S71-81; discussion S81-2.
7. Brooks BR, Miller RG, Swash M, Munsat TL. 2000. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord.* (5):293-9.

8. Cashman N, White C, Anderson F. 1999. Gender and presentation age in ALS patient care database. *Neurology*. 52:A166.
9. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. 1999. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). *J Neurol Sci*. 169(1-2):13-21.
10. Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier NL, Seilhean D, et al. 2008. Causes of death in a post-mortem series of ALS patients. *Amyotroph Lateral Scler*. 9:59–62.
11. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. 2008. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. *Neuroscience*. 26;155(3):567-72.
12. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A. 2008. Lithium delays progression of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA*. 105(6):2052-7.
13. Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, Paparelli A. 2008. Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium. *Autophagy*. 4(4):527-30.
14. Friedman SD, Dager SR, Parow A, Hirashima F, Demopoulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. 2004. Lithium and Valproic Acid Treatment Effects on Brain Chemistry in Bipolar Disorder. *Biol Psychiatry*. 56:340–34

15. Gooch CL, Weimer LH. 2007. The electrodiagnosis of neuropathy: basic principles and common pitfalls. *Neurol Clin.* 25(1):1-28
16. Haverkamp LJ, Appel V, Appel SH. 1995. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. *Brain.* 118:707–719.
17. Hu ML. 1994. Measurement of protein thiol groups and glutathione in plasma. *Methods Enzymol.* 233:380-5.
18. Huang YH, Shih CM, Huang CJ, Lin CM, Chou CM, Tsai ML, Liu TP, Chiu JF, Chen CT. 2006. Effects of cadmium on structure and enzymatic activity of Cu,Zn-SOD and oxidative status in neural cells. *J Cell Biochem.* 98(3):577-89
19. Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. 2009. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis . *J Neurosci.* 29(3):610-9.
20. Kraemer M, et al. 2010. Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. *Clin Neurol Neurosurg.* 2010. 112(2): 103-5.
21. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, Delumeau JC, Meininger V. 1996. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. *Neurology.* (6 Suppl 4):S242-50.
22. Lokesh C, Wijesekera, P Nigel Leigh. 2009. Amyotrophic lateral sclerosis. *Orphanet J Rare Dis.*; 4:3.
23. Martínez-Hernández HR, Fernández-González-Aragón MC, Burgos-Centeno J. 2008. Estudios neurofisiológicos para la detección del daño en la neurona motora superior e inferior en pacientes con esclerosis lateral amiotrófica. *Arch Neurocién (Méx).* 13(3):145-154.

24. Méndez-Armenta M, Ríos C. 2007. Cadmium neurotoxicity. *Environ. Toxicol. Pharmacol.* 23:350–8.
25. Miller RG, Mitchell JD, Lyon M, Moore DH. 2003. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Amyotroph Lateral Scler Other Motor Neuron Disord.* 4(3):191-206.
26. Parge HE, Hallewell RA, Tainer JA. 1992. Atomic structures of wild-type and thermostable mutant recombinant human Cu, Zn superoxide dismutase. *Proc Natl Acad Sci USA.* 89(22): 6109-13.
27. Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, Carri MT, Bendotti C. 2009. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice *Amyotroph Lateral Scler.* 23:1-8
28. Pradat PF et al. 2009. Update on fundamental and clinical research in amyotrophic lateral sclerosis. *Rev Neurol (Paris).* 165(6-7):532-41.
29. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. 1992. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. *Brain.* 115(2):495-520.
30. Roman GC. 1996. Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. *J Neurol Neurosurg Psychiatry.* 61:131–7.
31. Rowland LP. 2001. Amyotrophic Lateral Sclerosis. *N Engl J Med.* 22:1688-1700.
32. Soriani MH, Desnuelle C. Epidemiologie de la SLA. 2009. *Rev Neurol (Paris).* 165(8-9):627-40.

33. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. 2000. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population based study. *Arch Neurol.* 57:1171-1176.
34. Valdmanis PN, Rouleau GA. 2008. Genetics of familial amyotrophic lateral sclerosis. *Neurology.* 70(2):144-52.
35. Young W. 2009. Review of Lithium Effects on Brain and Blood. *Cell Transplant.* 18(9):951-75.
36. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, Lepore V, Serlenga L, Logroscino G. 2006. Signs and symptoms at diagnosis of amyotrophic lateral sclerosis: a population-based study in southern Italy. *Eur J Neurol.* 13(7):789-92.